Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Trends in Cardiac Monitoring after Ischemic Stroke and TIA: The Florida Puerto Rico Atrial Fibrillation Stroke Study
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
128

To evaluate trends in the utilization of continuous electrocardiogram(ECG) monitoring performed during hospital admission after ischemic stroke(IS) and transient ischemic attack(TIA) across a large network of hospitals in Florida and Puerto Rico(PR).

Practice patterns for type and duration of ECG monitoring after IS/TIA vary widely. Little is known regarding sex and race/ethnic disparities in the use of prolonged cardiac monitoring after stroke.

We identified 46,878 IS/TIA cases admitted to hospital with data on continuous ECG monitoring in the Florida Stroke Registry from 2016-2018. Univariate analysis was performed to determine the rate of continuous ECG monitoring and characteristics of patients receiving cardiac surface monitoring ≤7days and >7days, and implantable cardiac rhythm monitoring. Multivariate logistic regression was performed to identify factors associated with the types of monitoring.

Overall, 39,333 (84%) patients admitted for IS/TIA received continuous ECG monitoring during admission (mean age 71±14 years; 49% female; 63% White, 18% Black, 19% Hispanic). Compared to patients who received ECG monitoring, patients who did not were younger (mean age 70±15 years), PR-Hispanic (24% vs 4.3%), had TIA (13% vs 8%), Medicare insurance (42% vs 35%), large vessel disease (14% vs 9%) and greater admission NIHSS (median score 5 vs 4). After adjustment, smokers and patients >80years were less likely to receive ECG monitoring overall (OR 0.95, 95% CI 0.9-0.99 for both). Black race was associated with extended surface monitoring >7 days (OR 1.15, 95%CI 1.04-1.26), but negatively associated with implantable cardiac monitoring (OR 0.81, 95%CI 0.68-0.96). There were no sex differences observed. Patients with moderate to severe stroke had higher odds of extended surface monitoring >7days (OR 2.29, 95%CI 1.89-2.77), yet lower odds of implantable cardiac monitoring (OR 0.80, 95%CI 0.71-0.89).

Significant differences were found regarding age, race/ethnicity and stroke severity across different types and duration of cardiac monitoring performed after stroke/TIA.

Authors/Disclosures
Nicole B. Sur, MD (University of Miami)
PRESENTER
Dr. Sur has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Sur has received research support from Florida Stroke Registry. The institution of Dr. Sur has received research support from Miami CTSI & NIH/NINDS.
No disclosure on file
Sebastian Koch, MD (University of Miami) Dr. Koch has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Multiple Legal Matters. Dr. Koch has received stock or an ownership interest from Cerepeutics. Dr. Koch has received intellectual property interests from a discovery or technology relating to health care. Dr. Koch has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Hannah Gardener, ScD (University of Miami) Ms. Gardener has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intersocietal Accreditation Commission. Ms. Gardener has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ellipse Analytics. Ms. Gardener has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Baum Hedlund. Ms. Gardener has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with A Green Slate Consulting.
No disclosure on file
William S. Burgin, MD Dr. Burgin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for VuEssence. Dr. Burgin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Burgin has stock in VuEssence. The institution of Dr. Burgin has received research support from VuEssence. The institution of Dr. Burgin has received research support from Bristol-Myers Squibb. The institution of Dr. Burgin has received research support from ReNeuron.
David Z. Rose, MD (USF) Dr. Rose has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Boston Scientific. Dr. Rose has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Chiesi USA. Dr. Rose has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medtronic. Dr. Rose has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Boehringer Ingelheim . Dr. Rose has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL-Behring .
No disclosure on file
Jose G. Romano, MD, FÂé¶¹´«Ã½Ó³»­ (University of Miami, Miller School of Medicine) Dr. Romano has stock in Vycor Medical/NovaVision. The institution of Dr. Romano has received research support from NIH/NINDS. The institution of Dr. Romano has received research support from NIH/NHLBI.
Ralph L. Sacco, MD, MS, FAHA Dr. Sacco has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Sacco has received research support from NIH, NINDS, NCATS, NIMHD. The institution of Dr. Sacco has received research support from FL Department of Health. Dr. Sacco has received research support from University of Washington, Seattle. Dr. Sacco has received publishing royalties from a publication relating to health care.
Tatjana Rundek, MD, PhD The institution of Dr. Rundek has received research support from NIH.